EA201590469A1 - Двухслойный композиционный таблетированный состав, содержащий аторвастатин, ирбесартан и карбонат магния - Google Patents

Двухслойный композиционный таблетированный состав, содержащий аторвастатин, ирбесартан и карбонат магния

Info

Publication number
EA201590469A1
EA201590469A1 EA201590469A EA201590469A EA201590469A1 EA 201590469 A1 EA201590469 A1 EA 201590469A1 EA 201590469 A EA201590469 A EA 201590469A EA 201590469 A EA201590469 A EA 201590469A EA 201590469 A1 EA201590469 A1 EA 201590469A1
Authority
EA
Eurasian Patent Office
Prior art keywords
irbesartan
magnesium carbonate
composite tablet
composition containing
layer composite
Prior art date
Application number
EA201590469A
Other languages
English (en)
Other versions
EA030306B1 (ru
Inventor
Йонг Ил Ким
Дзунг Хиун Чо
Юн Йоунг Чой
Йоунг Кеун Чой
Дзае Хиун Парк
Дзонг Соо Воо
Original Assignee
Ханми Фарм. Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50183917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201590469(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ханми Фарм. Ко., Лтд. filed Critical Ханми Фарм. Ко., Лтд.
Publication of EA201590469A1 publication Critical patent/EA201590469A1/ru
Publication of EA030306B1 publication Critical patent/EA030306B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Раскрыты двухслойный композиционный таблетированный состав, включающий: (а) первый слой, содержащий ирбесартан или его фармацевтически приемлемую соль; и (b) второй слой, содержащий аторвастатин или его фармацевтически приемлемую соль и карбонат магния (MgCO), в массовом отношении от 1:4 до 1:5, и способ получения данного состава. При наличии отличных степеней растворения и биодоступности двухслойный композиционный таблеточный препарат применим в качестве терапии при гипертензии и гиперхолестеринемии.
EA201590469A 2012-08-31 2013-08-30 Двухслойная композиционная таблетированная лекарственная форма, содержащая аторвастатин, ирбесартан и карбонат магния EA030306B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120096477A KR20140028971A (ko) 2012-08-31 2012-08-31 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
PCT/KR2013/007838 WO2014035188A1 (en) 2012-08-31 2013-08-30 Bilayered composite tablet formulation comprising atorvastatin, irbesartan and magnesium carbonate

Publications (2)

Publication Number Publication Date
EA201590469A1 true EA201590469A1 (ru) 2015-06-30
EA030306B1 EA030306B1 (ru) 2018-07-31

Family

ID=50183917

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590469A EA030306B1 (ru) 2012-08-31 2013-08-30 Двухслойная композиционная таблетированная лекарственная форма, содержащая аторвастатин, ирбесартан и карбонат магния

Country Status (31)

Country Link
US (1) US20150209290A1 (ru)
EP (1) EP2890368A4 (ru)
JP (1) JP6363079B2 (ru)
KR (1) KR20140028971A (ru)
CN (1) CN104602677A (ru)
AR (1) AR092386A1 (ru)
AU (1) AU2013309686B2 (ru)
BR (1) BR112015004471A8 (ru)
CA (1) CA2882735A1 (ru)
CL (1) CL2015000402A1 (ru)
CR (1) CR20150115A (ru)
DO (1) DOP2015000040A (ru)
EA (1) EA030306B1 (ru)
EC (1) ECSP15010600A (ru)
GT (1) GT201500043A (ru)
IL (1) IL237424A0 (ru)
IN (1) IN2015DN01463A (ru)
MA (1) MA37951B2 (ru)
MX (1) MX354800B (ru)
MY (1) MY175897A (ru)
NI (1) NI201500027A (ru)
NZ (1) NZ706472A (ru)
PE (1) PE20150935A1 (ru)
PH (1) PH12015500394A1 (ru)
RU (1) RU2015111546A (ru)
SG (1) SG11201500584YA (ru)
TW (1) TWI651101B (ru)
UA (1) UA115995C2 (ru)
UY (1) UY35001A (ru)
WO (1) WO2014035188A1 (ru)
ZA (1) ZA201502156B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6981088B2 (ja) * 2017-01-27 2021-12-15 ニプロ株式会社 経口固形製剤
CR20190577A (es) * 2017-07-17 2020-01-29 Lilly Co Eli Composiciones farmacéuticas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
PE20030324A1 (es) 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
AR060354A1 (es) * 2006-04-06 2008-06-11 Schering Corp Terapias de combinacion antagonistas receptor trombina (tra)
KR20090114325A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 약제학적 제제
JP5534004B2 (ja) * 2010-03-29 2014-06-25 アステラス製薬株式会社 口腔内崩壊錠
KR101248804B1 (ko) * 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제

Also Published As

Publication number Publication date
ECSP15010600A (es) 2015-12-31
AU2013309686B2 (en) 2017-09-07
AR092386A1 (es) 2015-04-22
CA2882735A1 (en) 2014-03-06
CR20150115A (es) 2015-04-16
MA37951A1 (fr) 2018-06-29
JP6363079B2 (ja) 2018-07-25
AU2013309686A1 (en) 2015-02-26
WO2014035188A1 (en) 2014-03-06
PH12015500394A1 (en) 2015-04-27
BR112015004471A8 (pt) 2019-08-27
IL237424A0 (en) 2015-04-30
UY35001A (es) 2014-03-31
KR20140028971A (ko) 2014-03-10
JP2015530384A (ja) 2015-10-15
GT201500043A (es) 2017-08-24
EA030306B1 (ru) 2018-07-31
PE20150935A1 (es) 2015-06-20
BR112015004471A2 (pt) 2017-07-04
NZ706472A (en) 2018-02-23
US20150209290A1 (en) 2015-07-30
MY175897A (en) 2020-07-14
EP2890368A1 (en) 2015-07-08
TW201414507A (zh) 2014-04-16
UA115995C2 (uk) 2018-01-25
ZA201502156B (en) 2016-07-27
MX2015002526A (es) 2015-06-23
CN104602677A (zh) 2015-05-06
IN2015DN01463A (ru) 2015-07-03
MX354800B (es) 2018-03-22
DOP2015000040A (es) 2015-04-15
TWI651101B (zh) 2019-02-21
MA37951B2 (fr) 2019-12-31
RU2015111546A (ru) 2016-10-20
NI201500027A (es) 2017-01-04
EP2890368A4 (en) 2016-03-02
SG11201500584YA (en) 2015-02-27
CL2015000402A1 (es) 2015-06-05

Similar Documents

Publication Publication Date Title
PE20140163A1 (es) Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
UA107967C2 (en) Pharmaceutical composition in the form of bilayer tablets which contain inhibitor of hmg-coa reductase inhibitor and irbesartan
EA201291310A1 (ru) Композиция ингибитора jak для местного применения
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
WO2010132095A8 (en) Method and composition to improve absorption of therapeutic agents
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
EA201590474A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ
EA201590469A1 (ru) Двухслойный композиционный таблетированный состав, содержащий аторвастатин, ирбесартан и карбонат магния
WO2013062902A3 (en) Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with atorvastatin
EA201692090A1 (ru) Полициклические активаторы herg
TH155663A (ru)
WO2012111965A3 (ko) 경구투여용 탐술로신 또는 이의 약제학적으로 허용되는 염을 포함하는 서방성 삼중정제
RU2012133273A (ru) Сублингвальная форма 6-метил-2-этил-3-гидроксипиридина и ее применение в качестве средства, обладающего стимулирующей, анорексигенной, антидепрессивной, анксиолитической, противогипоксической, антиамнестической (ноотропной) и антиалкогольной активностью
TH117961B (th) องค์ประกอบไลโพโซม

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU